Entrada Therapeutics (TRDA) Research & Development (2022 - 2025)
Historic Research & Development for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $38.4 million.
- Entrada Therapeutics' Research & Development rose 2272.77% to $38.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year increase of 1791.07%. This contributed to the annual value of $125.3 million for FY2024, which is 2545.15% up from last year.
- Entrada Therapeutics' Research & Development amounted to $38.4 million in Q3 2025, which was up 2272.77% from $37.9 million recorded in Q2 2025.
- Entrada Therapeutics' Research & Development's 5-year high stood at $38.4 million during Q3 2025, with a 5-year trough of $15.7 million in Q4 2022.
- Over the past 4 years, Entrada Therapeutics' median Research & Development value was $28.3 million (recorded in 2023), while the average stood at $26.7 million.
- As far as peak fluctuations go, Entrada Therapeutics' Research & Development soared by 8036.98% in 2023, and later surged by 1211.55% in 2025.
- Quarter analysis of 4 years shows Entrada Therapeutics' Research & Development stood at $15.7 million in 2022, then soared by 80.37% to $28.3 million in 2023, then grew by 18.08% to $33.4 million in 2024, then increased by 14.83% to $38.4 million in 2025.
- Its Research & Development was $38.4 million in Q3 2025, compared to $37.9 million in Q2 2025 and $32.1 million in Q1 2025.